Box 6

Scope and Contents:

Correspondence regarding the distribution of Streptothricin- and Streptomycin-producing cultures in Great Britain.

Scope and Contents:

Correspondence and memoranda regarding standardization and assay data.

Scope and Contents:

File contains five reports, four of which are undated, including the background and discovery of Streptomycin* by SAW.

Scope and Contents:

Correspondence between SAW and W. Feldman of the University of Minnesota, The Mayo Foundation, and H. Hinshaw, also of The Mayo Foundation, regarding the development of Streptomycin and its dual use to treat tuberculosis and leprosy. There are also letters to Merck, the producers of Streptomycin and a Secret Memo dated September 27, 1944 from Dr. Richards, Columbia University, regarding a clinical case of a two-week old infant treated with Streptomycin.

Scope and Contents:

International correspondence and list of cultures sent abroad.

Scope and Contents:

A note on the front of the folder, penned by SAW, states, "The history of my relations with Merck & Co., the organization of the RR & EF, licensing of commercial manufacturers of Streptomycin."

Scope and Contents: A note on the front of the folder, penned by SAW, states, "The History pertaining to My Agreements with Merck & Co., the organization of the RR & EF, licensing of Streptomycin manufacturers." Agreements with Merck to provide funds to develop various fermentation processes and products of citric acid, chemotherapeutic agents; Memorandum of Invention,* September 3, 1942, on the " Isolation of Streptothricin from a soil actinomyces;"...

Scope and Contents:

Correspondence, reports, publications, and clippings including Civilian Production Administration, War Production Board; listing of royalties received by RR & EF for 1953; a Riter & Co. research report on the drug industry dated July 1953; U.S. Tariff Commission report on production and sales for 1952-5193 and 1963-1964; Department of Health, Education, and Welfare correspondence and report on ototoxicity of dihydro-streptomycin dated 1959.

Scope and Contents:

Original letters of contract with drug companies—see alphabetical list of drug companies in front of folder.

Scope and Contents:

U.S. Patent Office patent No. 2,449,866 dated September 21, 1948 for Streptomycin; copy of affidavit of SAW dated October 10, 1950 on the process of production of Streptomycin; patent policy of the Institute; the patent portfolio of RR & EF dated October 18, 1956. Remainder of folder contains copies of letters referred to in Folder 9 and lists of companies and addresses.